| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f6be7b5f316f050e9151b3afd8936f7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3061 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2005-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69c3bc4a43030ae1232de13fe8a3ed22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_859352c889f82fbd2609317bfdfe0b6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c481b7bfb96f9e2172bfd49213cc777b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f986f58b5592617f672070931a584eb3 |
| publicationDate |
2007-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20070102513-A |
| titleOfInvention |
Cytotoxic antibodies against type V lymphoid hematopoietic proliferation |
| abstract |
The present invention relates to monoclonal antibodies against the CD20 antigen, wherein the variable region of each light chain is selected from the murine nucleic acid sequence SEQ ID No. Encoded by a sequence sharing at least 70% identity with 5, and the variable region of each heavy chain is selected from the murine nucleic acid sequence SEQ ID No. Encoded by sequences that share at least 70% identity with 7, wherein the constant regions of these light and heavy chains are constant regions derived from non-murine species; The invention also relates to the use of such antibodies in the activation of FcγRIIIA receptors in immune effector cells and in the manufacture of medicaments, in particular for the treatment of leukemia or lymphoma. |
| priorityDate |
2004-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |